Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report)’s share price crossed below its 50-day moving average during trading on Monday .The stock has a 50-day moving average of $0.62 and ...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...

Adaptimmune Therapeutics plc (ADAP) stock price is 0.58 and Adaptimmune Therapeutics plc (ADAP) 10-day simple moving average is 0.58. Adaptimmune Therapeutics plc (ADAP) stock price is 0.58 and ...

On Wednesday, Adaptimmune Therapeutics plc (NASDAQ:ADAP) received an upgrade from Jones Trading, shifting from a Hold to a Buy rating. The firm has also set a new price target ...

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nurix Therapeutics (NRIX – Research Report), ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...